Developing hormone receptor-based medicines, for lif
A clinical trial evaluating an oral medicine to potentially treat stress urinary incontinence (SUI)
Our lead product candidate is focused on stress urinary incontinence, which affects up to 35 percent of adult women. Learn about our pipeline »
April 16, 2018
GTx to Present Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence at a Podium Presentation at 2018 AUA Annual Meeting MORE »April 9, 2018
GTx Announces Early Completion of Patient Enrollment in the ASTRID Trial, a Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence MORE »Key Opinion Leader (KOL) Luncheon
09/28/17 12:00 p.m. ETWebcast Presentation »
Key Opinion Leader (KOL) Luncheon Presentation [PDF] »